Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dysbiosis is a pathological state characterized by an imbalance in the composition, diversity, or functional capacity of the microbiome, most commonly within the gastrointestinal tract (NIH, StatPearls, 2023). It involves the loss of beneficial commensal bacteria, a reduction in microbial richness, and the expansion of potentially harmful pathobionts, which together disrupt host-microbe symbiosis. This condition is a hallmark of various chronic inflammatory and metabolic diseases, as it leads to increased intestinal permeability ('leaky gut') and systemic inflammation (Nature Reviews Microbiology, 2019). While dysbiosis is not a single molecular target like a protein or receptor, it serves as a therapeutic focal point for interventions such as fecal microbiota transplants (FMT), probiotics, and prebiotics, which aim to restore ecological balance. Monitoring and correcting dysbiosis is critical in the management of refractory infections like Clostridioides difficile and chronic conditions like inflammatory bowel disease (PubMed, 2022).
Restoration of the microbial community structure and diversity to re-establish host-microbe metabolic and immune homeostasis.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dysbiosis.